Don't blaze the trailblazer TRAIL too early [12]

Lancet

Volumn 356, Issue 9246, 2000, Pages 2014-

  De Vries, E G E ^a   Van Der Graaf, W T A ^a   Heijenbrok, F J ^a   Hoekstra, H J ^a   De Jong, S ^a  

^a UNIVERSITY MEDICAL CENTER GRONINGEN   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC AGENT; LIGAND; MELPHALAN; MESSENGER RNA; RECOMBINANT TUMOR NECROSIS FACTOR ALPHA; TUMOR NECROSIS FACTOR RELATED APOPTOSIS INDUCING LIGAND; UNCLASSIFIED DRUG;

ANIMAL CELL; ANIMAL EXPERIMENT; APOPTOSIS; CANCER CELL; DRUG SAFETY; HUMAN; HUMAN CELL; LETTER; LIVER CELL; MOUSE; NONHUMAN; PRIORITY JOURNAL; TUMOR XENOGRAFT;

EID: 0034627187     PISSN: 01406736     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0140-6736(05)72991-3     Document Type: Letter

References (5)

1. Human brain-cell death induced by tumour-necrosis-factor-related apoptosis-inducing ligand (TRAIL)
2. Tumoricidal activity of tumor necrosis factor-related apoptosis-inducing ligand in vivo
3. Safety and antitumor activity of recombinant soluble Apo2 ligand
4. The pharmacokinetics of Apo2Ligand/TRAIL(Apo2L/TRAIL) following a single iv bolus dose to chimpanzees
5. Apoptosis induced in normal human hepatocytes by tumor necrosis factor-related apoptosis-inducing ligand